Jurnal
SINTA 1
Cohort Prospective Study to Evaluate Immunogenicity of Epodion® (Biosimilar Epoetin-α) in Anemia Associated with Chronic Kidney Disease (CKD) Patients
ACTA MEDICA INDONESIANA · Vol. 54 No. 3 (2022)
ISSN 2338-2732, 0125-9326
Terbit 2022-09-24
Penerbit The Indonesian Society of Internal Medicine
Bahasa eng
Abstrak
Background: Anemia due to chronic kidney disease (CKD) is often associated with decreased erythropoietin (EPO) levels in the blood. Treatments available are improving blood iron levels and administration of exogenous EPO (rhEPO). This study aims to assess the safety and immunogenicity of Epodion, a biosimilar rhEPO product, in haemodialysis patients with CKD-associated anaemia in three Indonesian hospitals. Methods: This prospective, open label, single arm, and multicenter study enrolled patients with anemia associated with CKD under hemodialysis treatment. Patient eligibility was assessed within the 4-week screening period. Blood samples for determination of erythropoietin antibody (Anti-Drug Antibody) were taken at week-0, 24, and 52 using a validated and highly sensitive bridging ELISA method. Evaluation of Neutralizing Antibody (NAb) was carried out to confirm the impact of the antibody to pharmacological activity (e.g., antibody-mediated PRCA) when the ADA detection of patients was positive after screening and confirmatory assay. Results: Results from all tested patients show that Epodion could maintain hemoglobin and hematocrit levels. ADA detection using ELISA assay yielded negative results for all plasma samples of week-24 and week-52, so the evaluation of NAb was not carried out. No adverse events were considered relevant to tested product. Conclusion: This study proves no immunogenic effect of Epodion on stimulating immune system’s antibodies in Indonesian patients with CKD-associated anemia.
Jaringan kolaborasi para penulis
15 penulis ·
45 tautan kepenulisan bersama
Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.
Organisasi berbeda
Organisasi sama
Afiliasi tidak diketahui
Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.
Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title xml:lang="en-US">Cohort Prospective Study to Evaluate Immunogenicity of Epodion® (Biosimilar Epoetin-α) in Anemia Associated with Chronic Kidney Disease (CKD) Patients</dc:title>
<dc:creator>Angginy, Nova</dc:creator>
<dc:creator>Suh, Chang Woo</dc:creator>
<dc:creator>Jonny, Jonny</dc:creator>
<dc:creator>Mahnulia, Nuly Juariah</dc:creator>
<dc:creator>Suhardjono, Suhardjono</dc:creator>
<dc:subject xml:lang="en-US">Anemia</dc:subject>
<dc:subject xml:lang="en-US">anti-drug antibody</dc:subject>
<dc:subject xml:lang="en-US">anti-rhEPO</dc:subject>
<dc:subject xml:lang="en-US">chronic kidney disease</dc:subject>
<dc:subject xml:lang="en-US">erythropoietin</dc:subject>
<dc:description xml:lang="en-US">Background: Anemia due to chronic kidney disease (CKD) is often associated with decreased erythropoietin (EPO) levels in the blood. Treatments available are improving blood iron levels and administration of exogenous EPO (rhEPO). This study aims to assess the safety and immunogenicity of Epodion, a biosimilar rhEPO product, in haemodialysis patients with CKD-associated anaemia in three Indonesian hospitals. Methods: This prospective, open label, single arm, and multicenter study enrolled patients with anemia associated with CKD under hemodialysis treatment. Patient eligibility was assessed within the 4-week screening period. Blood samples for determination of erythropoietin antibody (Anti-Drug Antibody) were taken at week-0, 24, and 52 using a validated and highly sensitive bridging ELISA method. Evaluation of Neutralizing Antibody (NAb) was carried out to confirm the impact of the antibody to pharmacological activity (e.g., antibody-mediated PRCA) when the ADA detection of patients was positive after screening and confirmatory assay. Results: Results from all tested patients show that Epodion could maintain hemoglobin and hematocrit levels. ADA detection using ELISA assay yielded negative results for all plasma samples of week-24 and week-52, so the evaluation of NAb was not carried out. No adverse events were considered relevant to tested product. Conclusion: This study proves no immunogenic effect of Epodion on stimulating immune system’s antibodies in Indonesian patients with CKD-associated anemia.</dc:description>
<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
<dc:date>2022-09-24</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:type xml:lang="en-US">prospective, open label, single arm, and multicenter study</dc:type>
<dc:format>application/pdf</dc:format>
<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/1946</dc:identifier>
<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 54 No. 3 (2022): Acta Medica Indonesiana; 397</dc:source>
<dc:source>2338-2732</dc:source>
<dc:source>0125-9326</dc:source>
<dc:language>eng</dc:language>
<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/1946/pdf</dc:relation>
<dc:rights xml:lang="en-US">Copyright (c) 2022 Nova Angginy, Chang Woo Suh, Jonny Jonny, Nuly Juariah Mahnulia, Suhardjono Suhardjono</dc:rights>
</oai_dc:dc>
Sitasi dan pengindeksan
OpenAlex
Belum diperiksa
Crossref
Tidak ditemukan
Jumlah menurut tiap indeks pada 9 Nov 2026; setiap indeks menghitung sitasi dengan cara berbeda.
Sitasi artikel ini
APA 7
Angginy, N., Suh, C. W., Jonny, J., Mahnulia, N. J., & Suhardjono, S. (2022). Cohort Prospective Study to Evaluate Immunogenicity of Epodion® (Biosimilar Epoetin-α) in Anemia Associated with Chronic Kidney Disease (CKD) Patients. ACTA MEDICA INDONESIANA, 54(3). http://www.actamedindones.org/index.php/ijim/article/view/1946
Salin
IEEE
N. Angginy, C. W. Suh, J. Jonny, N. J. Mahnulia, and S. Suhardjono, “Cohort Prospective Study to Evaluate Immunogenicity of Epodion® (Biosimilar Epoetin-α) in Anemia Associated with Chronic Kidney Disease (CKD) Patients,” ACTA MEDICA INDONESIANA, vol. 54, no. 3, 2022.
Salin
Dibuat dari metadata jurnal; periksa nama penulis sebelum dipakai.